Scale-up considerations for improved yield in upstream viral vector production

Abstract

Strategy at Oxford Biomedica Peter has over 30 years' experience in the biopharmaceutical industry. He joined Oxford Biomedica in 2011, providing technical and scientific leadership. In his current role, he is responsible for overseeing strategic and operational planning to develop the Company's capabilities and capacity to support future business growth. Peter is a Fellow of the Institution of Chemical Engineers and the Royal Academy of Engineering Visiting Professor in Manufacturing of Advanced Therapies at Aston University.

Lentiviral vectors: key challenges and new developments

“…This growing market demands transformative solutions capable of turning a production system designed to provide viral vectors for research, preclinical studies, and small phase I/II clinical trials into fully industrial processes. Many recent reviews describe the key points of the roadmap for manufacturing viral vectors [1,2].…”